CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
9673 ETCTN PART A: A Multi-Institutional Phase 2 Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal PART B: A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal Adult CIRB - Early Phase Emphasis
9676 ETCTN A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors Adult CIRB - Early Phase Emphasis
9681 ETCTN A Phase 1 Study of Cabozantinib plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary Tumors. Adult CIRB - Early Phase Emphasis
9706 ETCTN Randomized phase II study to assess the role of Nivolumab as single agent to eliminate minimal residual disease and maintain remission in acute myelogenous leukemia (AML) patients after chemotherapy (REMAIN Trial) Adult CIRB - Early Phase Emphasis
9742 ETCTN Multicenter Phase II Study of Nivolumab in Previously Treated Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma Adult CIRB - Early Phase Emphasis
9767 ETCTN An Open Label; Multicenter; Single arm Phase II study to evaluate the Activity and Tolerability of the novel mTOR Inhibitor; MLN0128 (TAK-228); in patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the urothelial tract whose tumors harbor a TSC1 and/or a TSC2 mutation Adult CIRB - Early Phase Emphasis
9775 ETCTN A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL) Adult CIRB - Early Phase Emphasis
9782 ETCTN A Phase 1 Study of Talazoparib (BMN 673) in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumors Adult CIRB - Early Phase Emphasis
9824 ETCTN A Phase 1 Study of alisertib (MLN8237) in combination with mFOLFOX in gastrointestinal tumors Adult CIRB - Early Phase Emphasis
9825 ETCTN A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer Adult CIRB - Early Phase Emphasis